In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Conclave 2025, Vikrant Shrotriya, Managing Director of Novo Nordisk India, said that a weight loss drug is not a magic pill.

Martin Makary, President Donald Trump's nominee to run the U.S. FDA, told lawmakers on Thursday he would convene a committee ...

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...

The FDA recently announced that Novo Nordisk’s semaglutide GLP-1 medication (Ozempic and Wegovy) is no longer in short supply ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

Could taking tiny fractions of the normal prescribed dose of a medication offer a brilliant way to benefit from the drug, ...

While GLP-1 drugs are currently available in the market, the Food and Drug Administration (FDA) had declared a shortage of semaglutide supply since 2022 after its popularity skyrocketed following news ...

Stifel downgraded Novo Nordisk (NVO) to Hold from Buy with a price target of DKK 700, down from DKK 780. Novo is “no longer the same stock that ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...